Mycoplasma pneumoniae cells, small bacteria that are naturally adapted to the...
Mycoplasma pneumoniae cells, small bacteria that are naturally adapted to the human lung

Image credit: María Lluch/CRG

News • Repurposing bacteria

‘Living medicine’ could treat drug-resistant infections

Researchers at the Centre for Genomic Regulation (CRG) and Pulmobiotics S.L have created the first ‘living medicine’ to treat antibiotic-resistant bacteria growing on the surfaces of medical implants.

The researchers created the treatment by removing a common bacteria’s ability to cause disease and repurposing it to attack harmful microbes instead. The study is published in the journal Molecular Systems Biology

The experimental treatment was tested on infected catheters in vitro, ex vivo and in vivo, successfully treating infections across all three testing methods. According to the authors, injecting the therapy under the skin of mice treated infections in 82% of the treated animals. The findings are an important first step for the development of new treatments for infections affecting medical implants such as catheters, pacemakers and prosthetic joints. These are highly resistant to antibiotics and account for 80% of all infections acquired in hospital settings.

The new treatment specifically targets biofilms, colonies of bacterial cells that stick together on a surface. The surfaces of medical implants are ideal growing conditions for biofilms, where they form impenetrable structures that prevent antibiotics or the human immune system from destroying the bacteria embedded within. Biofilm-associated bacteria can be a thousand times more resistant to antibiotics than free-floating bacteria.

Photo
Staphylococcus aureus under the transmission electron microscope

Image source: National Institutes of Health (NIH), Staph aureus outside a white blood cell, marked as public domain, details at Wikimedia Commons

Staphylococcus aureus is one of the most common species of biofilm-associated bacteria. S. aureus infections do not respond to conventional antibiotics, requiring patients to surgically remove any infected medical implants. Alternative therapies include the use of antibodies or enzymes, but these are broad-spectrum treatments that are highly toxic for normal tissues and cells, causing undesired side effects. The authors of the study hypothesised that introducing living organisms that directly produce enzymes in the local vicinity of biofilms is a safer and cheaper way of treating infections. Bacteria are an ideal vector, as they have small genomes that can be modified using simple genetic manipulation.

The researchers chose to engineer Mycoplasma pneumoniae, a common species of bacteria that lacks a cell wall, making it easier to release the therapeutic molecules that fight infection while also assisting it in evading detection from the human immune system. Other advantages of using M. pneumoniae as a vector include its low risk of mutating new abilities, and its inability to transfer any of its modified genes to other microbes living nearby. M. pneumoniae was first modified so that it would not cause illness. Further tweaks made it produce two different enzymes that dissolve biofilms and attacks the cell walls of the bacteria embedded within. The researchers also modified the bacteria so that it secretes antimicrobial enzymes more efficiently.

One of the great benefits of the technology is that once they reach their destination, bacterial vectors offer continuous and localised production of the therapeutic molecule

Luis Serrano

The researchers first aim to use the modified bacteria to treat biofilms building around breathing tubes, as M. pneumoniae is naturally adapted to the lung. “Our technology, based on synthetic biology and live biotherapeutics, has been designed to meet all safety and efficacy standards for application in the lung, with respiratory diseases being one of the first targets. Our next challenge is to address high-scale production and manufacturing, and we expect to start clinical trials in 2023,” says María Lluch, co-corresponding author of the study and Chief Science Officer of Pulmobiotics.

The modified bacteria may also have long-term applications for other diseases. “Bacteria are ideal vehicles for ‘living medicine’ because they can carry any given therapeutic protein to treat the source of a disease. One of the great benefits of the technology is that once they reach their destination, bacterial vectors offer continuous and localised production of the therapeutic molecule. Like any vehicle, our bacteria can be modified with different payloads that target different diseases, with potentially more applications in the future,” says ICREA Research Professor Luis Serrano, Director of the CRG and co-author of the study.


Source: Centre for Genomic Regulation

08.10.2021

Related articles

Photo

News • Tracking the spread and evolution of superbugs

Mapping the movement of people (and their pathogen travel companions)

Integrating bacterial genomic data with detailed human mobility data makes it possible to see how pathogens causing pneumonia and meningitis, move between regions and evolve over time.

Photo

News • Heteroresistance

Researchers discover new mechanisms behind antibiotic resistance

A new study explores the phenomenon of heteroresistance in bacteria, which is a key driver of antibiotic resistance. Two new discoveries could impact the development of future AMR strategies.

Photo

News • “Defanging” dangerous bacteria

Pathoblockers: a future alternative to antibiotics?

Researchers have succeeded in developing “pathoblockers” that provide protection against the most common pneumonia-inducing pathogens, even if they are resistant to antibiotics.

Related products

Subscribe to Newsletter